Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…
Anomaly detection use case will be demonstrated live with partner Q-KON at AfricaCom 2025 HERNDON, Va., Oct. 28, 2025 /PRNewswire/…
At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base…
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this…
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by The Hong Kong University of Science and Technology…
SANTA CLARA, Calif., Sept. 4, 2025 /PRNewswire/ -- Trianz, a digital transformation software and solutions company, announced today that it…
MUMBAI, India and ISELIN, N.J. , Sept. 2, 2025 /PRNewswire/ -- Hexaware Technologies, a global provider of IT solutions and services,…
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…
Hyundai Motor Group highlighted hydrogen’s role in decarbonization and energy resilience during two high-level dialogues at the 16th Clean Energy…
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…